Nicolas Gabriel Biro, MD
Ophthalmology · Burbank
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
- Since medical school
- 21 years
- University of South Florida College of Medicine, 2005
Offices
6 locations · A Center for Visioncare Surgical and Medical Group · First Choice Physician Partners · Pacific Eye Institute A Medical Group Inc · Paul J Dougherty M D Inc
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Biro’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C172433 · Current
Licensed to practise in California · since 2021 · expires 2027-04-30 · University of South Florida College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Original Medicare doctor bills
$148,854
Medicare paid this office $148,854 for 357 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of excessive skin and fat of upper eyelid | 23 | $18,080 | $786 |
| Established patient problem focused exam of visual system | 143 | $12,927 | $76 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 18 | $12,077 | $575 |
| Removal of excessive skin and fat of upper eyelid | 19 | $11,695 | $616 |
| Repair of tendon of upper eyelid | 11 | $9,804 | $891 |
See all 19 services
| Removal of excessive skin and fat of upper eyelid | 23 | $18,080 | $786 |
| Established patient problem focused exam of visual system | 143 | $12,927 | $76 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 18 | $12,077 | $575 |
| Removal of excessive skin and fat of upper eyelid | 19 | $11,695 | $616 |
| Repair of tendon of upper eyelid | 11 | $9,804 | $891 |
| Return visit (30+ min) | 83 | $9,273 | $98 |
| Removal of growth of eyelid | 38 | $7,676 | $197 |
| Photography of content of eyes | 243 | $6,072 | $19 |
| Botox | 11 | $5,670 | None |
| Short return visit (20+ min) | 63 | $4,258 | $62 |
| New patient visit (30+ min) | 56 | $3,978 | $71 |
| New patient visit (45+ min) | 31 | $3,211 | $104 |
| Exam of visual field with extended testing | 47 | $2,400 | $48 |
| Face injection for nerve paralysis | 11 | $2,253 | $125 |
| Probing of nasal tear duct | 14 | $1,978 | $141 |
| New patient problem focused exam of visual system | 27 | $1,712 | $63 |
| Removal of eyelashes | 11 | $1,172 | $107 |
| Injection into skin growth, 1-7 growths | 12 | $609 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $50 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of excessive skin and fat of upper eyelid | 11 | – | – | 55 | 53 | 42 |
| Removal of growth of eyelid | 18 | – | 15 | 28 | 31 | 39 |
| Probing of nasal tear duct | 17 | 11 | – | 21 | 14 | 14 |
| Injection into skin growth, 1-7 growths | – | – | 23 | 21 | – | 14 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | – | – | – | – | 18 | 21 |
| Repair of tendon of upper eyelid | – | – | – | 12 | – | 11 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
357 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 14% · Women 67% · Also on Medicaid 36% · Health risk score 1.25. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 74% · Diabetes 40% · Coronary heart disease 27% · Chronic kidney disease 26% · Depression 20% · Heart failure 18% · Atrial fibrillation 16% · COPD 14% · Cancer 12% · Dementia 8% · Stroke 8%.
The office billed $617,192, Medicare allowed $196,021 and paid $148,854; for 2,384 services of 51 kinds; $5,722 of it was for drugs given in the office and $143,132 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 357 | 2,384 | 74 | 1.25 | $617,192 | $148,854 |
| 2023 | 307 | 2,004 | 74 | 1.38 | $657,526 | $153,182 |
| 2022 | 369 | 1,860 | 74 | 1.30 | $771,540 | $132,736 |
| 2021 | 194 | 791 | 72 | 1.33 | $154,771 | $46,940 |
| 2020 | 218 | 752 | 72 | 1.53 | $202,626 | $59,340 |
| 2019 | 368 | 1,272 | 71 | 1.43 | $306,961 | $86,502 |
| 2018 | 412 | 1,153 | 70 | 1.69 | $322,360 | $93,944 |
| 2017 | 398 | 1,107 | 71 | 1.64 | $302,459 | $80,891 |
| 2016 | 345 | 843 | 71 | 1.75 | $303,327 | $76,140 |
| 2015 | 246 | 447 | 70 | 1.72 | $163,465 | $29,643 |
| 2014 | 204 | 262 | 71 | 1.62 | $80,473 | $17,158 |
| 2013 | 134 | 284 | 71 | 1.48 | $29,635 | $14,611 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Removal of excessive skin and fat of upper eyelid | 29 | $23,603 | $814 |
| New patient visit (45+ min) | 116 | $16,418 | $142 |
| Removal of excessive skin and fat of upper eyelid | 24 | $16,125 | $672 |
| Return visit (30+ min) | 86 | $12,961 | $113 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 17 | $11,038 | $613 |
| Established patient problem focused exam of visual system | 93 | $7,131 | $59 |
| Photography of content of eyes | 184 | $5,910 | $21 |
| Removal of growth of eyelid | 29 | $4,839 | $156 |
| Probing of nasal tear duct | 14 | $2,040 | $146 |
| Established patient complete exam of visual system | 13 | $1,367 | $105 |
| New patient visit (30+ min) | 12 | $1,081 | $90 |
| New patient problem focused exam of visual system | 11 | $614 | $56 |
| Exam of visual field with extended testing | 11 | $535 | $49 |
| Exam of visual field with limited testing | 13 | $294 | $23 |
2022: 14 services
| Removal of excessive skin and fat of upper eyelid | 55 | $37,822 | $688 |
| Established patient problem focused exam of visual system | 292 | $29,578 | $71 |
| Repair of tendon of upper eyelid | 11 | $8,055 | $671 |
| Removal of growth of eyelid | 26 | $7,063 | $252 |
| Photography of content of eyes | 146 | $2,925 | $19 |
| Probing of nasal tear duct | 20 | $2,841 | $135 |
| Exam of visual field with limited testing | 100 | $2,761 | $26 |
| Established patient complete exam of visual system | 19 | $2,271 | $108 |
| New patient visit (30+ min) | 19 | $1,805 | $95 |
| Exam of visual field with extended testing | 32 | $1,607 | $47 |
| New patient problem focused exam of visual system | 23 | $1,358 | $59 |
| Injection into skin growth, 1-7 growths | 18 | $1,026 | $49 |
| Exam to measure eye deviation and range of motion | 15 | $858 | $54 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $84 | None |
2021: 13 services
| Short return visit (20+ min) | 57 | $7,050 | $79 |
| Removal of growth of eyelid | 15 | $4,076 | $272 |
| New patient visit (30+ min) | 41 | $3,704 | $90 |
| Established patient problem focused exam of visual system | 34 | $3,104 | $78 |
| Injection into skin growth, 1-7 growths | 14 | $1,048 | $46 |
| Exam of visual field with extended testing | 19 | $988 | $52 |
| New patient complete exam of visual system | 13 | $969 | $75 |
| Established patient problem focused exam of visual system | 16 | $957 | $42 |
| Established patient complete exam of visual system | 17 | $858 | $50 |
| Photography of content of eyes | 21 | $410 | $20 |
| Imaging of optic nerve | 11 | $350 | $29 |
| Imaging of optic nerve | 11 | $180 | $16 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $25 | None |
2020: 12 services
| New patient visit (30+ min) | 57 | $4,993 | $88 |
| Established patient problem focused exam of visual system | 45 | $4,416 | $74 |
| Short return visit (20+ min) | 29 | $3,663 | $65 |
| Established patient complete exam of visual system | 24 | $2,288 | $88 |
| New patient complete exam of visual system | 18 | $2,035 | $113 |
| Established patient problem focused exam of visual system | 33 | $1,985 | $43 |
| Probing of nasal tear duct | 11 | $1,209 | $110 |
| Exam of visual field with extended testing | 26 | $1,156 | $44 |
| Established patient complete exam of visual system | 16 | $1,010 | $63 |
| New patient complete exam of visual system | 11 | $900 | $82 |
| Imaging of optic nerve | 17 | $664 | $33 |
| Imaging of optic nerve | 18 | $420 | $20 |
2019: 17 services
| Established patient complete exam of visual system | 72 | $8,756 | $102 |
| Removal of excessive skin and fat of upper eyelid | 11 | $7,266 | $661 |
| New patient visit (30+ min) | 77 | $6,824 | $89 |
| Established patient problem focused exam of visual system | 52 | $5,831 | $80 |
| Removal of growth of eyelid | 17 | $4,362 | $242 |
| New patient complete exam of visual system | 34 | $4,321 | $127 |
| Exam of visual field with extended testing | 65 | $4,219 | $59 |
| Established patient problem focused exam of visual system | 67 | $3,790 | $42 |
| Short return visit (20+ min) | 48 | $3,718 | $64 |
| Probing of nasal tear duct | 16 | $2,298 | $135 |
| New patient visit (45+ min) | 16 | $2,084 | $130 |
| Imaging of optic nerve | 33 | $1,476 | $33 |
| New patient complete exam of visual system | 18 | $1,327 | $74 |
| Exam to measure eye deviation and range of motion | 13 | $899 | $56 |
| Established patient complete exam of visual system | 11 | $792 | $72 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $568 | $24 |
| Imaging of optic nerve | 17 | $359 | $19 |
2018: 20 services
| Established patient complete exam of visual system | 96 | $11,343 | $102 |
| New patient complete exam of visual system | 65 | $8,250 | $127 |
| Established patient problem focused exam of visual system | 66 | $7,173 | $78 |
| New patient visit (30+ min) | 64 | $6,377 | $100 |
| Established patient problem focused exam of visual system | 84 | $5,789 | $43 |
| Exam of visual field with extended testing | 56 | $4,035 | $58 |
| Short return visit (20+ min) | 32 | $3,201 | $68 |
| New patient visit (45+ min) | 13 | $2,062 | $159 |
| Probing of nasal tear duct | 14 | $1,825 | $130 |
| Imaging of optic nerve | 44 | $1,793 | $33 |
| New patient complete exam of visual system | 17 | $1,460 | $86 |
| Examination of eye by ophthalmoscope with retinal drawing | 30 | $1,329 | $23 |
| New patient problem focused exam of visual system | 13 | $995 | $77 |
| Exam to measure eye deviation and range of motion | 12 | $813 | $58 |
| Examination of eye by ophthalmoscope with retinal drawing | 15 | $644 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 17 | $616 | $29 |
| Imaging of retina | 13 | $537 | $38 |
| Imaging of optic nerve | 16 | $303 | $19 |
| Examination of eye by ophthalmoscope with retinal drawing | 12 | $274 | $21 |
| Ultrasound scan of cornea to determine thickness | 11 | $149 | $14 |
2017: 20 services
| Established patient complete exam of visual system | 81 | $9,853 | $100 |
| New patient complete exam of visual system | 78 | $9,357 | $120 |
| Established patient problem focused exam of visual system | 86 | $8,484 | $71 |
| Established patient problem focused exam of visual system | 83 | $5,340 | $39 |
| New patient visit (30+ min) | 41 | $3,922 | $96 |
| Exam of visual field with extended testing | 53 | $3,657 | $58 |
| New patient complete exam of visual system | 33 | $2,422 | $73 |
| Imaging of optic nerve | 38 | $1,464 | $31 |
| New patient problem focused exam of visual system | 17 | $1,207 | $71 |
| Examination of eye by ophthalmoscope with retinal drawing | 28 | $1,148 | $23 |
| Established patient complete exam of visual system | 20 | $951 | $48 |
| Examination of eye by ophthalmoscope with retinal drawing | 29 | $906 | $31 |
| Examination of eye by ophthalmoscope with retinal drawing | 20 | $835 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 29 | $772 | $26 |
| Imaging of retina | 14 | $526 | $35 |
| Imaging of optic nerve | 18 | $399 | $19 |
| Exam of the internal drainage system of eye | 14 | $268 | $16 |
| Exam of the internal drainage system of eye | 11 | $263 | $24 |
| Imaging of retina | 12 | $239 | $20 |
| Ultrasound scan of cornea to determine thickness | 12 | $156 | $13 |
2016: 15 services
| Repair of tendon of upper eyelid | 13 | $9,039 | $646 |
| Established patient problem focused exam of visual system | 79 | $7,621 | $73 |
| New patient complete exam of visual system | 58 | $7,048 | $122 |
| Established patient problem focused exam of visual system | 86 | $5,898 | $44 |
| Established patient complete exam of visual system | 38 | $4,428 | $108 |
| New patient complete exam of visual system | 27 | $2,168 | $80 |
| New patient visit (30+ min) | 20 | $1,957 | $98 |
| Established patient complete exam of visual system | 30 | $1,855 | $62 |
| Exam of visual field with extended testing | 29 | $1,680 | $58 |
| New patient problem focused exam of visual system | 20 | $1,306 | $65 |
| Short return visit (20+ min) | 15 | $1,252 | $63 |
| Imaging of optic nerve | 20 | $763 | $38 |
| Examination of eye by ophthalmoscope with retinal drawing | 19 | $654 | $33 |
| Imaging of optic nerve | 20 | $619 | $24 |
| Exam of the internal drainage system of eye | 16 | $286 | $18 |
2015: 8 services
| Short return visit (20+ min) | 91 | $4,235 | $37 |
| Established patient problem focused exam of visual system | 64 | $3,676 | $47 |
| New patient complete exam of visual system | 34 | $2,623 | $77 |
| Short return visit (20+ min) | 31 | $2,183 | $64 |
| Established patient complete exam of visual system | 16 | $1,132 | $71 |
| Imaging of retina | 22 | $606 | $24 |
| Imaging of optic nerve | 19 | $516 | $25 |
| Ultrasound scan to determine eye length and lens power | 11 | $274 | $25 |
2014: 5 services
| Established patient problem focused exam of visual system | 86 | $4,634 | $49 |
| Emergency department visit with low level of medical decision making | 45 | $2,360 | $50 |
| New patient complete exam of visual system | 22 | $1,915 | $87 |
| Short return visit (20+ min) | 31 | $1,464 | $44 |
| Emergency department visit with moderate level of medical decision making | 12 | $1,172 | $98 |
2013: 6 services
| Emergency department visit with low level of medical decision making | 54 | $2,685 | $50 |
| Emergency department visit with moderate level of medical decision making | 24 | $2,298 | $96 |
| Established patient complete exam of visual system | 14 | $1,889 | $105 |
| New patient complete exam of visual system | 14 | $1,425 | $102 |
| Established patient problem focused exam of visual system | 12 | $1,173 | $69 |
| Exam of visual field with extended testing | 14 | $895 | $56 |
Medicaid work
$8,951 in 2024
Medicaid paid $8,951 for 636 billed services this clinician did in 2024, up to 38 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 194 | $4,148 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 110 | $3,840 |
| XTRNL OCULAR PHOTOG W/I&R DOCMT MED PROGRESS | 264 | $747 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 13 | $216 |
| New patient visit (45+ min) | 55 | $0 |
| 2024 | 636 | 5 | 38 | $8,951 |
| 2023 | 739 | 4 | 43 | $19,177 |
| 2022 | 563 | 2 | 55 | $16,089 |
| 2021 | 193 | 5 | 25 | $12,416 |
| 2020 | 336 | 5 | 23 | $18,163 |
| 2019 | 1,424 | 7 | 54 | $62,922 |
| 2018 | 2,361 | 10 | 66 | $127,199 |
See the largest Medicaid services in earlier years
2023
| New patient visit (45+ min) | 133 | $7,159 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 174 | $5,419 |
| Return visit (30+ min) | 154 | $5,247 |
| XTRNL OCULAR PHOTOG W/I&R DOCMT MED PROGRESS | 278 | $1,352 |
2022
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 543 | $15,556 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 20 | $533 |
2021
| Short return visit (20+ min) | 77 | $5,319 |
| New patient visit (30+ min) | 58 | $4,692 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 26 | $914 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 17 | $901 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 15 | $590 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 181 | $10,793 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 97 | $6,211 |
| New patient visit (30+ min) | 14 | $1,159 |
| TOBACCO NON-USER | 13 | $0 |
| No documentation of pain assessment, reason not given | 31 | $0 |
2019
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 287 | $28,321 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 427 | $22,304 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 74 | $11,017 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 39 | $963 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 12 | $316 |
| TOBACCO NON-USER | 259 | $0 |
| No documentation of pain assessment, reason not given | 326 | $0 |
2018
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 446 | $51,777 |
| OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST | 304 | $41,616 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 469 | $31,210 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve | 42 | $1,602 |
| Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2) | 13 | $809 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 17 | $185 |
| TOBACCO NON-USER | 437 | $0 |
| Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD) | 28 | $0 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 60 | $0 |
| No documentation of pain assessment, reason not given | 545 | $0 |
Drugs they prescribed that Part D paid
$46,414
Pharmacies billed $46,414 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (17 of 1,412) in 2024. A higher opioid share than 9 in 10 peers; the typical ophthalmology clinician is at 0%.
1,248 generic and 164 brand-name prescriptions · $46,414 in drug cost · 26 antibiotic prescriptions to 23 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Erythromycin | 758 | $12,988 | $17 |
| Restasis | 14 | $9,790 | $699 |
| Fluorometholone | 49 | $3,978 | $81 |
| Tobradex | 11 | $2,811 | $256 |
| Prednisolone Acetate | 52 | $1,904 | $37 |
See all 13 drugs
| Erythromycin | 758 | $12,988 | $17 |
| Restasis | 14 | $9,790 | $699 |
| Fluorometholone | 49 | $3,978 | $81 |
| Tobradex | 11 | $2,811 | $256 |
| Prednisolone Acetate | 52 | $1,904 | $37 |
| Neomycin-Polymyxin-Dexameth | 118 | $1,381 | $12 |
| Diazepam | 234 | $362 | $2 |
| Azelastine | 25 | $253 | $10 |
| Ofloxacin | 13 | $230 | $18 |
| Amoxicillin-Clavulanate Potass | 12 | $162 | $14 |
| Dorzolamide-Timolol | 12 | $121 | $10 |
| Hydrocodone-Acetaminophen | 13 | $63 | $5 |
| Latanoprost | 13 | $21 | $2 |
Year by year
| 2024 | 1,412 | 721 | 1% (17) | 12% | $46,414 |
| 2023 | 1,088 | 620 | 4% (41) | 20% | $65,416 |
| 2022 | 682 | 444 | 0% (0) | None | $47,687 |
| 2021 | 379 | 161 | 0% (0) | 36% | $39,740 |
| 2020 | 454 | 153 | 0% (0) | 42% | $48,637 |
| 2019 | 604 | 220 | 0% (0) | None | $56,866 |
| 2018 | 804 | 251 | None | 37% | $90,636 |
| 2017 | 540 | 188 | 0% (0) | 41% | $58,494 |
| 2016 | 207 | 94 | None | 38% | $14,406 |
| 2015 | 41 | 23 | 0% (0) | 39% | $4,404 |
| 2014 | 25 | 12 | 0% (0) | None | $1,026 |
| 2013 | 23 | None | None | None | $497 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Restasis | 20 | $18,272 | $914 |
| Erythromycin | 463 | $7,980 | $17 |
| Fluorometholone | 52 | $4,489 | $86 |
| Bacitracin | 25 | $4,212 | $168 |
| Prednisolone Acetate | 69 | $3,437 | $50 |
| Neomycin-Polymyxin-Dexameth | 138 | $2,561 | $19 |
| Ofloxacin | 18 | $273 | $15 |
| Latanoprost | 20 | $269 | $13 |
| Amoxicillin-Clavulanate Potass | 12 | $211 | $18 |
| Diazepam | 137 | $204 | $1 |
| Acetaminophen-Codeine | 23 | $109 | $5 |
| Hydrocodone-Acetaminophen | 15 | $50 | $3 |
2022: 7 drugs
| Restasis | 19 | $20,078 | $1,057 |
| Erythromycin | 324 | $3,784 | $12 |
| Fluorometholone | 24 | $2,005 | $84 |
| Neomycin-Polymyxin-Dexameth | 116 | $1,783 | $15 |
| Prednisolone Acetate | 28 | $1,350 | $48 |
| Latanoprost | 34 | $685 | $20 |
| Azelastine | 14 | $287 | $21 |
2021: 9 drugs
| Restasis | 23 | $16,422 | $714 |
| Xiidra | 11 | $6,969 | $634 |
| Fluorometholone | 16 | $1,512 | $94 |
| Erythromycin | 105 | $1,070 | $10 |
| Latanoprost | 54 | $757 | $14 |
| Prednisolone Acetate | 15 | $697 | $46 |
| Dorzolamide-Timolol | 26 | $510 | $20 |
| Neomycin-Polymyxin-Dexameth | 31 | $460 | $15 |
| Azelastine | 14 | $123 | $9 |
2020: 13 drugs
| Restasis | 18 | $10,885 | $605 |
| Cequa | 12 | $6,171 | $514 |
| Pyridostigmine Bromide Er | 11 | $3,282 | $298 |
| Pazeo | 14 | $2,978 | $213 |
| Combigan | 14 | $2,571 | $184 |
| Olopatadine | 25 | $2,149 | $86 |
| Fluorometholone | 32 | $2,011 | $63 |
| Prednisolone Acetate | 20 | $959 | $48 |
| Erythromycin | 86 | $942 | $11 |
| Latanoprost | 68 | $774 | $11 |
| Dorzolamide-Timolol | 16 | $617 | $39 |
| Azelastine | 22 | $352 | $16 |
| Neomycin-Polymyxin-Dexameth | 23 | $297 | $13 |
2019: 15 drugs
| Restasis | 31 | $18,777 | $606 |
| Olopatadine | 55 | $4,065 | $74 |
| Pazeo | 17 | $3,364 | $198 |
| Fluorometholone | 43 | $3,162 | $74 |
| Simbrinza | 12 | $1,989 | $166 |
| Bacitracin | 21 | $1,843 | $88 |
| Acetazolamide | 12 | $1,225 | $102 |
| Erythromycin | 97 | $1,195 | $12 |
| Prednisolone Acetate | 21 | $1,037 | $49 |
| Brimonidine | 15 | $1,035 | $69 |
| Latanoprost | 97 | $976 | $10 |
| Neomycin-Polymyxin-Dexameth | 48 | $645 | $13 |
| Pyridostigmine | 13 | $414 | $32 |
| Dorzolamide-Timolol | 18 | $328 | $18 |
| Azelastine | 11 | $260 | $24 |
2018: 16 drugs
| Restasis | 82 | $42,493 | $518 |
| Pyridostigmine Bromide Er | 18 | $8,521 | $473 |
| Lotemax | 15 | $4,229 | $282 |
| Combigan | 13 | $3,419 | $263 |
| Brimonidine | 31 | $3,057 | $99 |
| Bacitracin | 22 | $1,891 | $86 |
| Latanoprost | 184 | $1,676 | $9 |
| Fluorometholone | 22 | $1,623 | $74 |
| Olopatadine | 19 | $1,438 | $76 |
| Prednisolone Acetate | 26 | $1,104 | $42 |
| Pyridostigmine | 18 | $837 | $46 |
| Dorzolamide-Timolol | 53 | $761 | $14 |
| Erythromycin | 84 | $755 | $9 |
| Neomycin-Polymyxin-Dexameth | 54 | $716 | $13 |
| Azelastine | 29 | $704 | $24 |
| Timolol Maleate | 34 | $235 | $7 |
2017: 13 drugs
| Restasis | 50 | $24,921 | $498 |
| Fluorometholone | 41 | $3,214 | $78 |
| Bacitracin | 32 | $2,999 | $94 |
| Combigan | 15 | $2,989 | $199 |
| Pataday | 12 | $2,020 | $168 |
| Pyridostigmine | 17 | $1,730 | $102 |
| Latanoprost | 122 | $1,274 | $10 |
| Olopatadine | 14 | $1,152 | $82 |
| Azelastine | 26 | $1,047 | $40 |
| Prednisolone Acetate | 21 | $930 | $44 |
| Dorzolamide-Timolol | 28 | $530 | $19 |
| Erythromycin | 33 | $357 | $11 |
| Neomycin-Polymyxin-Dexameth | 22 | $304 | $14 |
2016: 5 drugs
| Fluorometholone | 13 | $1,083 | $83 |
| Azelastine | 14 | $718 | $51 |
| Latanoprost | 46 | $605 | $13 |
| Erythromycin | 44 | $504 | $11 |
| Neomycin-Polymyxin-Dexameth | 18 | $369 | $21 |
2015: 1 drug
| Erythromycin | 12 | $136 | $11 |
Money from drug and device companies
$26,147 in 2025
| 2025 | 3 | 60 | $24,863 | $26,147 |
| 2024 | 2 | 39 | $5,738 | $7,635 |
| 2023 | 2 | 65 | $36,513 | $39,435 |
| 2022 | 6 | 24 | $1,275 | $2,131 |
| 2021 | 4 | 7 | None | $165 |
| 2020 | 5 | 9 | None | $303 |
| 2019 | 5 | 6 | None | $346 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Tepezza | $25,982 | 56 payments
|
| Glaukos | Idosetr | $93 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $72 | 3 payments
|
See all 60 published payments
| Amgen | Meals · 2025-12-22 | Tepezza | $26 |
| Amgen | Meals · 2025-12-08 | Tepezza | $11 |
| Amgen | Meals · 2025-11-24 | Tepezza | $20 |
| Amgen | Paid to speak or teach · 2025-11-21 | Tepezza | $2,550 |
| Amgen | Travel · 2025-11-21 | Tepezza | $35 |
| Amgen | Meals · 2025-11-18 | Tepezza | $5 |
| Amgen | Meals · 2025-11-17 | Tepezza | $126 |
| Amgen | Meals · 2025-10-27 | Tepezza | $9 |
| Amgen | Meals · 2025-10-22 | Tepezza | $8 |
| Amgen | Meals · 2025-10-09 | Tepezza | $27 |
| Tarsus Pharmaceuticals | Meals · 2025-10-09 | Xdemvy | $19 |
| Amgen | Meals · 2025-10-07 | Tepezza | $27 |
| Amgen | Paid to speak or teach · 2025-09-17 | Tepezza | $2,550 |
| Amgen | Meals · 2025-09-16 | Tepezza | $24 |
| Amgen | Meals · 2025-09-08 | Tepezza | $20 |
| Amgen | Meals · 2025-09-02 | Tepezza | $7 |
| Amgen | Meals · 2025-08-27 | Tepezza | $17 |
| Amgen | Meals · 2025-08-26 | Tepezza | $25 |
| Amgen | Meals · 2025-08-25 | Tepezza | $12 |
| Tarsus Pharmaceuticals | Meals · 2025-08-21 | Xdemvy | $28 |
| Amgen | Meals · 2025-08-12 | Tepezza | $10 |
| Amgen | Meals · 2025-08-12 | Tepezza | $45 |
| Amgen | Meals · 2025-08-11 | Tepezza | $10 |
| Amgen | Meals · 2025-08-06 | Tepezza | $6 |
| Amgen | Paid to speak or teach · 2025-08-01 | Tepezza | $2,550 |
| Amgen | Meals · 2025-07-29 | Tepezza | $143 |
| Amgen | Meals · 2025-07-22 | Tepezza | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-07-17 | Xdemvy | $25 |
| Glaukos | Meals · 2025-07-15 | Idosetr | $93 |
| Amgen | Meals · 2025-07-09 | Tepezza | $6 |
| Amgen | Meals · 2025-07-07 | Tepezza | $12 |
| Amgen | Travel · 2025-06-25 | Tepezza | $24 |
| Amgen | Travel · 2025-06-25 | Tepezza | $23 |
| Amgen | Meals · 2025-06-23 | Tepezza | $10 |
| Amgen | Paid to speak or teach · 2025-06-19 | Tepezza | $2,550 |
| Amgen | Meals · 2025-06-17 | Tepezza | $68 |
| Amgen | Travel · 2025-06-10 | Tepezza | $35 |
| Amgen | Meals · 2025-06-09 | Tepezza | $7 |
| Amgen | Paid to speak or teach · 2025-06-06 | Tepezza | $2,550 |
| Amgen | Paid to speak or teach · 2025-06-06 | Tepezza | $425 |
| Amgen | Meals · 2025-06-03 | Tepezza | $119 |
| Amgen | Meals · 2025-06-02 | Tepezza | $16 |
| Amgen | Meals · 2025-05-27 | Tepezza | $6 |
| Amgen | Meals · 2025-05-19 | Tepezza | $9 |
| Amgen | Paid to speak or teach · 2025-04-28 | Tepezza | $425 |
| Amgen | Paid to speak or teach · 2025-04-28 | Tepezza | $2,550 |
| Amgen | Meals · 2025-04-08 | Tepezza | $27 |
| Amgen | Meals · 2025-04-07 | Tepezza | $19 |
| Amgen | Paid to speak or teach · 2025-04-02 | Tepezza | $1,063 |
| Amgen | Meals · 2025-04-01 | Tepezza | $5 |
| Amgen | Travel · 2025-03-11 | Tepezza | $35 |
| Amgen | Paid to speak or teach · 2025-02-26 | Tepezza | $2,550 |
| Amgen | Travel · 2025-02-26 | Tepezza | $5 |
| Amgen | Travel · 2025-02-26 | Tepezza | $8 |
| Amgen | Meals · 2025-02-24 | Tepezza | $11 |
| Amgen | Paid to speak or teach · 2025-02-06 | Tepezza | $2,550 |
| Amgen | Meals · 2025-02-04 | Tepezza | $13 |
| Amgen | Meals · 2025-01-17 | Tepezza | $30 |
| Amgen | Meals · 2025-01-14 | Tepezza | $10 |
| Amgen | Paid to speak or teach · 2025-01-09 | Tepezza | $2,550 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,635
| Amgen | Tepezza | $7,601 | 38 payments
|
| Alcon Vision | Rocklatan | $34 | 1 payment
|
2023: $39,435
| Horizon Therapeutics plc | Tepezza | $39,310 | 64 payments
|
| Sun Pharmaceutical Industries | Cequa | $125 | 1 payment
|
2022: $2,131
| Horizon Therapeutics plc | Tepezza | $1,662 | 17 payments
|
| Sight Sciences | Omni(R) Surgical System (US) | $161 | 2 payments
|
| Oyster Point Pharma | Tyrvaya | $124 | 2 payments
|
| Mallinckrodt Hospital Products | Acthar | $100 | 1 payment
|
| BioTissue Holdings | Prokera | $60 | 1 payment
|
| Abbvie | Vuity | $24 | 1 payment
|
2021: $165
| Horizon Therapeutics plc | Tepezza | $81 | 4 payments
|
| Regeneron Pharmaceuticals | None | $40 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis Iol | $24 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $20 | 1 payment
|
2020: $303
| Mallinckrodt Hospital Products | Acthar | $194 | 4 payments
|
| Horizon Therapeutics plc | Krystexxa | $45 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $24 | 1 payment
|
| Alexion Pharmaceuticals | Soliris | $20 | 1 payment
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
2019: $346
| Sun Pharmaceutical Industries | Cequa | $106 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Ultra | $76 | 1 payment
|
| Allergan | Lumigan | $75 | 1 payment
|
| Galderma Laboratories L.P. | None | $66 | 1 payment
|
| Mallinckrodt Enterprises | Acthar | $23 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1497959332
- Licence
- CA C172433, NY 247912California C172433: Current · expires 2027-04-30
- Trained
- University of South Florida College of Medicine, 2005 · 21 years ago
- Group
- A Center for Visioncare Surgical and Medical Group · First Choice Physician Partners · Pacific Eye Institute A Medical Group Inc · Paul J Dougherty M D Inc
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207WX0200X (207WX0200X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 13311 Galewood St, Sherman Oaks, CA, 91423
- NPI first listed
- 2007-06-13
- NPI last updated
- 2026-02-12
- NPI record certified
- 2024-05-20
This is when the NPI record was last certified, not a medical board exam.